NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free MGNX Stock Alerts $14.72 -0.24 (-1.60%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$14.29▼$15.2550-Day Range$10.75▼$21.4752-Week Range$4.29▼$21.88Volume808,749 shsAverage Volume1.41 million shsMarket Capitalization$918.97 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get MacroGenics alerts: Email Address MacroGenics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside15.2% Upside$17.00 Price TargetShort InterestBearish9.56% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$637,187 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.79) to $0.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.25 out of 5 starsMedical Sector441st out of 938 stocksPharmaceutical Preparations Industry208th out of 432 stocks 2.4 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, MacroGenics has a forecasted upside of 15.2% from its current price of $14.76.Amount of Analyst CoverageMacroGenics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.56% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in MacroGenics has recently increased by 11.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 2.2 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MacroGenics this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $637,187.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to grow in the coming year, from ($2.79) to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -92.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -92.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBuy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.And for the first time in 2024, he’s sharing his strategy for free. About MacroGenics Stock (NASDAQ:MGNX)MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More MGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGNX Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comMGNX Apr 2024 10.000 putMarch 16, 2024 | finance.yahoo.comMGNX Dec 2024 17.500 putMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 15, 2024 | ca.finance.yahoo.comMGNX Mar 2024 22.500 putMarch 14, 2024 | msn.comThe Potential of MacroGenics’ (NASDAQ:MGNX) Pipeline is Driving the StockMarch 14, 2024 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call TranscriptMarch 11, 2024 | realmoney.thestreet.comMacroGenics price target raised by $6 at JMP Securities, here's whyMarch 11, 2024 | msn.com3 Best Stocks to Buy Now, 3/11/2024, According to Top AnalystsMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 11, 2024 | realmoney.thestreet.comMacroGenics price target raised by $12 at Citi, here's whyMarch 11, 2024 | markets.businessinsider.comMaintaining Market Outperform for MacroGenics with Increased Confidence in ADC Leadership and Clinical ProspectsMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for MacroGenics on Promising Pipeline and Strong FinancialsMarch 10, 2024 | fool.comMacroGenics (NASDAQ: MGNX)March 8, 2024 | fool.comMacroGenics (MGNX) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comMGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023March 7, 2024 | finance.yahoo.comMacrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ...March 7, 2024 | benzinga.comMacrogenics: Q4 Earnings InsightsMarch 7, 2024 | msn.comMacroGenics GAAP EPS of -$0.15 misses by $0.58, revenue of $58.8M misses by $22.08MMarch 7, 2024 | globenewswire.comMacroGenics Provides Update on Corporate Progress and 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comInsider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX)March 6, 2024 | msn.comMacroGenics Q4 2023 Earnings PreviewMarch 4, 2024 | benzinga.comAnalyst Expectations For Macrogenics's FutureMarch 4, 2024 | realmoney.thestreet.comMacroGenics price target raised by $12 at BTIG, here's whyMarch 2, 2024 | finance.yahoo.comAre Investors Undervaluing MacroGenics, Inc. (NASDAQ:MGNX) By 48%?March 1, 2024 | globenewswire.comMacroGenics to Participate in Upcoming Investor ConferencesFebruary 29, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX)February 27, 2024 | globenewswire.comMacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference CallSee More Headlines Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees339Year Founded2000Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$24.00 Low Stock Price Target$12.00 Potential Upside/Downside+15.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,060,000.00 Net Margins-15.42% Pretax Margin-15.42% Return on Equity-88.49% Return on Assets-43.12% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.46 Sales & Book Value Annual Sales$58.75 million Price / Sales15.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book6.00Miscellaneous Outstanding Shares62,430,000Free Float56,189,000Market Cap$921.47 million OptionableOptionable Beta2.12 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Scott Koenig M.D. (Age 72)Ph.D., President, CEO & Director Comp: $1.06MMr. James Karrels (Age 57)Senior VP, CFO & Corporate Secretary Comp: $626.83kMr. Eric Blasius Risser (Age 51)Chief Operating Officer Comp: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 57)Senior Vice President of Technical Operations Comp: $550.97kDr. Ezio Bonvini (Age 70)Senior VP of Research & Chief Scientific Officer Comp: $612.21kMr. Jeffrey Stuart Peters (Age 53)Senior VP, General Counsel & Corporate Compliance Officer Dr. Stephen L. Eck M.D. (Age 69)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Comp: $577.62kMs. Lynn Cilinski (Age 66)VP, Controller & Treasurer More ExecutivesKey CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTORIC PharmaceuticalsNASDAQ:ORICArcturus TherapeuticsNASDAQ:ARCTCassava SciencesNASDAQ:SAVAPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 105,530 shares on 3/11/2024Ownership: 6.903%Wellington Management Group LLPSold 10,397 shares on 3/5/2024Ownership: 0.384%Perceptive Advisors LLCBought 611,932 shares on 2/26/2024Ownership: 0.987%Jeffrey Stuart PetersSold 16,124 sharesTotal: $277,655.28 ($17.22/share)Price T Rowe Associates Inc. MDSold 4,198 shares on 2/16/2024Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions MGNX Stock Analysis - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price target for 2024? 7 brokerages have issued 1 year price objectives for MacroGenics' stock. Their MGNX share price targets range from $12.00 to $24.00. On average, they expect the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 15.2% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2024? MacroGenics' stock was trading at $9.62 on January 1st, 2024. Since then, MGNX stock has increased by 53.4% and is now trading at $14.76. View the best growth stocks for 2024 here. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.49. The biopharmaceutical company had revenue of $10.72 million for the quarter, compared to analysts' expectations of $25.70 million. MacroGenics had a negative trailing twelve-month return on equity of 88.49% and a negative net margin of 15.42%. During the same quarter in the previous year, the business posted $0.21 earnings per share. What ETF holds MacroGenics' stock? iShares Genomics Immunology and Healthcare ETF holds 221,160 shares of MGNX stock, representing 1.03% of its portfolio. What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Bellevue Group AG (16.05%), Armistice Capital LLC (7.37%), Vanguard Group Inc. (6.95%), Vanguard Group Inc. (6.90%), Frazier Life Sciences Management L.P. (3.87%) and Wasatch Advisors LP (2.09%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGNX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.